Organicell Regenerative Medicine, Inc.
Organicell Regenerative Medicine, Inc. (OCEL) Revenue
Annual & quarterly revenue history · segment & region breakdown
OCEL · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsOrganicell Regenerative Medicine, Inc. trailing twelve-month (TTM) revenue is $0.01B, an increase of 12.53% year-over-year from $0.01B in FY2025.
Revenue trend
2025 – 2011 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-10-31 | $0.01B | +$0.00B | +12.53% |
| 2024-10-31 | $0.00B | +$0.00B | +1.35% |
| 2023-10-31 | $0.00B | -$0.00B | -29.78% |
| 2022-10-31 | $0.01B | +$0.00B | +15.96% |
| 2021-10-31 | $0.01B | +$0.00B | +83.18% |
| 2020-10-31 | $0.00B | +$0.00B | +79.51% |
| 2019-10-31 | $0.00B | +$0.00B | +76.49% |
| 2018-10-31 | $0.00B | +$0.00B | +69.26% |
| 2017-10-31 | $0.00B | +$0.00B | +208.22% |
| 2016-10-31 | $0.00B | +$0.00B | +25.23% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Organicell Regenerative Medicine, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Organicell Regenerative Medicine, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Organicell Regenerative Medicine, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
OCEL revenue · 4 questionsOCEL's trailing twelve-month (TTM) revenue is $0.01B. That is an increase of 12.53% year-over-year from $0.01B in FY2025.
▸ Source: FMP · Organicell Regenerative Medicine, Inc. SEC filings · GAAP · Organicell Regenerative Medicine, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026